 Pseudomonas originosa has become a serious threat in hospital-acquired infections, particularly among critically ill and immunosuppressed patients. This is due to the emergence of drug-resistant strains which can lead to high mortality rates. To address this issue, researchers are developing novel anti-infective agents such as antibiotics, anti-virulent compounds, and combination treatments. These include targeting the pathogen's metabolism, virulence, or its ability to resist antibiotics. Additionally, clinicians must identify risk factors for resistance and understand how it affects patient outcomes. Finally, researchers should continue to explore new therapeutic options and optimize existing ones. This article was authored by Matteo Bassetti, Antonio Vina, Antony Croxato, and others.